Cargando…
Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway
Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of esophageal cancer (EC). ESCC accounts for 90% of EC. Recurrence after primary treatment is the main reason for poor survival. Therefore, recurrence prevention is a promising strategy for extendin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372369/ https://www.ncbi.nlm.nih.gov/pubmed/34422635 http://dx.doi.org/10.3389/fonc.2021.683241 |
_version_ | 1783739780612227072 |
---|---|
author | Wu, Xiangyu Wang, Zitong Jiang, Yanan Zhou, Hao Li, Ang Wei, Yaxing Bao, Zhuo Wang, Donghao Zhao, Jimin Chen, Xinhuan Guo, Yaping Dong, Zigang Liu, Kangdong |
author_facet | Wu, Xiangyu Wang, Zitong Jiang, Yanan Zhou, Hao Li, Ang Wei, Yaxing Bao, Zhuo Wang, Donghao Zhao, Jimin Chen, Xinhuan Guo, Yaping Dong, Zigang Liu, Kangdong |
author_sort | Wu, Xiangyu |
collection | PubMed |
description | Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of esophageal cancer (EC). ESCC accounts for 90% of EC. Recurrence after primary treatment is the main reason for poor survival. Therefore, recurrence prevention is a promising strategy for extending the 5-year survival rate. Here, we found tegaserod maleate could inhibit ESCC proliferation both in vivo and in vitro. Proteomics analysis revealed that tegaserod maleate suppressed the peroxisome signaling pathway, in which the key molecules peroxisome membrane protein 11B (PEX11B) and peroxisome membrane protein 13 (PEX13) were downregulated. The immunofluorescence, catalase activity assay, and reactive oxygen species (ROS) confirmed that downregulation of these proteins was related to impaired peroxisome function. Furthermore, we found that PEX11B and PEX13 were highly expressed in ESCC, and knockout of PEX11B and PEX13 further demonstrated the antitumor effect of tegaserod maleate. Importantly, tegaserod maleate repressed ESCC tumor growth in a patient-derived xenograft (PDX) model in vivo. Our findings conclusively demonstrated that tegaserod maleate inhibits the proliferation of ESCC by suppressing the peroxisome pathway. |
format | Online Article Text |
id | pubmed-8372369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83723692021-08-19 Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway Wu, Xiangyu Wang, Zitong Jiang, Yanan Zhou, Hao Li, Ang Wei, Yaxing Bao, Zhuo Wang, Donghao Zhao, Jimin Chen, Xinhuan Guo, Yaping Dong, Zigang Liu, Kangdong Front Oncol Oncology Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of esophageal cancer (EC). ESCC accounts for 90% of EC. Recurrence after primary treatment is the main reason for poor survival. Therefore, recurrence prevention is a promising strategy for extending the 5-year survival rate. Here, we found tegaserod maleate could inhibit ESCC proliferation both in vivo and in vitro. Proteomics analysis revealed that tegaserod maleate suppressed the peroxisome signaling pathway, in which the key molecules peroxisome membrane protein 11B (PEX11B) and peroxisome membrane protein 13 (PEX13) were downregulated. The immunofluorescence, catalase activity assay, and reactive oxygen species (ROS) confirmed that downregulation of these proteins was related to impaired peroxisome function. Furthermore, we found that PEX11B and PEX13 were highly expressed in ESCC, and knockout of PEX11B and PEX13 further demonstrated the antitumor effect of tegaserod maleate. Importantly, tegaserod maleate repressed ESCC tumor growth in a patient-derived xenograft (PDX) model in vivo. Our findings conclusively demonstrated that tegaserod maleate inhibits the proliferation of ESCC by suppressing the peroxisome pathway. Frontiers Media S.A. 2021-08-04 /pmc/articles/PMC8372369/ /pubmed/34422635 http://dx.doi.org/10.3389/fonc.2021.683241 Text en Copyright © 2021 Wu, Wang, Jiang, Zhou, Li, Wei, Bao, Wang, Zhao, Chen, Guo, Dong and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wu, Xiangyu Wang, Zitong Jiang, Yanan Zhou, Hao Li, Ang Wei, Yaxing Bao, Zhuo Wang, Donghao Zhao, Jimin Chen, Xinhuan Guo, Yaping Dong, Zigang Liu, Kangdong Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway |
title | Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway |
title_full | Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway |
title_fullStr | Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway |
title_full_unstemmed | Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway |
title_short | Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway |
title_sort | tegaserod maleate inhibits esophageal squamous cell carcinoma proliferation by suppressing the peroxisome pathway |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372369/ https://www.ncbi.nlm.nih.gov/pubmed/34422635 http://dx.doi.org/10.3389/fonc.2021.683241 |
work_keys_str_mv | AT wuxiangyu tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT wangzitong tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT jiangyanan tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT zhouhao tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT liang tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT weiyaxing tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT baozhuo tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT wangdonghao tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT zhaojimin tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT chenxinhuan tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT guoyaping tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT dongzigang tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway AT liukangdong tegaserodmaleateinhibitsesophagealsquamouscellcarcinomaproliferationbysuppressingtheperoxisomepathway |